Hunan Jingfeng Pharmaceutical Co

Hunan Jingfeng Pharmaceutical Co Working Capital

The Working Capital of Hunan Jingfeng Pharmaceutical Co (000908.SZ) as of Oct 24, 2026 is -253.12 M CNY. In the previous year, Working Capital was -950.34 M CNY — a change of -73.37% (higher).

Working Capital

-253.12 MCNY

YoY

-73.37%

Last updated:

Working Capital of Hunan Jingfeng Pharmaceutical Co is 2025 -253.12 M CNY. Working Capital of Hunan Jingfeng Pharmaceutical Co was 2024 -950.34 M CNY. It decreases by -73.37% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hunan Jingfeng Pharmaceutical Co Stock analysis

What does Hunan Jingfeng Pharmaceutical Co do? Hunan Jingfeng Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical and biological drugs. Its main product categories include cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs, and anti-infective drugs. The company distributes these products domestically and also engages in commodity import and export trading, business management and consulting, and medical technology consulting services. Sales are primarily directed at the domestic market with no mention of international distribution channels. The firm's revenue streams are derived from pharmaceutical sales, particularly in cardiovascular, oncology, and infectious disease treatments, alongside ancillary services such as medical technology consulting. The domestic market remains the sole focus for product distribution, with no indication of export-oriented sales. The company's operations are centered on drug manufacturing and related consulting services, targeting healthcare providers and domestic consumers through established distribution networks. Hunan Jingfeng Pharmaceutical's business model emphasizes product diversity across multiple therapeutic areas, including cardiovascular, oncology, and infectious diseases. The company's revenue is driven by both direct pharmaceutical sales and ancillary consulting services, with all activities confined to the domestic market. The absence of international operations or export-focused strategies is consistent with the business description provided. Hunan Jingfeng Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hunan Jingfeng Pharmaceutical Co stock

Working Capital of Hunan Jingfeng Pharmaceutical Co is -253.12 M CNY in 2025.

Working Capital of Hunan Jingfeng Pharmaceutical Co changed from -950.34 M CNY to -253.12 M CNY, representing a -73.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Hunan Jingfeng Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Hunan Jingfeng Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Hunan Jingfeng Pharmaceutical Co

All Key Metrics — Hunan Jingfeng Pharmaceutical Co